Medics in Ukraine work amid shelling and worsening health crisis

European News

Ukraine’s health emergency is worsening, WHO have shared as the conflict with Russia continues, and staff face burnout and increased shelling. So far, there have been 434 attacks on healthcare facilities in the country.

615 such attacks on healthcare have been reported worldwide this year, WHO shared via a tracker.

With winter approaching, the health organisation’s concerns for healthcare in the region have been exacerbated.

In June, Mariupol had a population standing at around 100,000, where prior to the war, around 430,000 lived in the city.

“It’s kind of falling off the news in a way...but this is an emergency of public health,” WHO's Ukraine emergency coordinator Heather Papowitz told Reuters.

“Getting access is the biggest issue, it is what keeps us up at night,” said Papowitz. Currently, global healthcare services such as WHO are facing challenges getting medicines into areas of conflict for people with chronic conditions, or to treat physical and mental trauma. Papowitz shared that WHO’s biggest concern was for the areas currently inaccessible to its teams, due to conflict or Russian occupation. These areas include the Eastern Donbas region and Kherson, to the south.

In May, Reuters published the statistic that at least 3,000 people had died in Ukraine due to the inability to access treatments for chronic diseases. This problem of access was directly caused by the February invasion of the country by Russian forces.

Now, disease control is playing a part in the worsening health crisis of the country. There have, further, been concerns over the risk of cholera in the region, though Papowitz underlined that no cholera outbreaks have yet been reported.

Europe Plans Further Antibiotic Shortage Countermeasures

Following the increase in respiratory infections, the continuing cost of living crisis and the Russia-Ukraine conflict, Europe is planning countermeasures for further antibiotic shortages

AstraZeneca Moves Manufacturing To Ireland Due To Britain’s Tax Regime

AstraZeneca has announced plans to open a new facility in Ireland, previously planned for northwest England

Genoscience Pharma Received Orphan Drug Designation For Hepatocellular Carcinoma Drug

Genoscience Pharma has received FDA ODD for its hepatocellular carcinoma drug

European Commission Approves Dupixent® As The First And Only Targeted Medicine For Prurigo Nodularis

Regeneron Pharmaceuticals and Sanofi have announced that the European Commission (EC) has expanded the marketing authorisation for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.

ServBlock Secures EU Funding For Pharma Manufacturing Data Space

ServBlock, an Irish start-up, and Irish Manufacturing Research (IMR), have been given EU funding to build a data exchange system for outsourced pharmaceutical manufacturing.

Europe Plans Further Antibiotic Shortage Countermeasures

AstraZeneca Moves Manufacturing To Ireland Due To Britain’s Tax Regime

Genoscience Pharma Received Orphan Drug Designation For Hepatocellular Carcinoma Drug

European Commission Approves Dupixent® As The First And Only Targeted Medicine For Prurigo Nodularis

ServBlock Secures EU Funding For Pharma Manufacturing Data Space

Pharmafocus

Categories

Social Footprints